基于网络药理学的抗肿瘤药物发现策略

被引：22

作者：

肖智勇

周文霞

张永祥

机构：

[1] 军事医学科学院毒物药物研究所

来源：

国际药学研究杂志 | 2014年 / 41卷 / 01期

关键词：

肿瘤; 网络药理学; 新药研发;

D O I：

10.13220/j.cnki.jipr.2014.01.001

中图分类号：

R96 [药理学]; R979.1 [抗肿瘤、抗癌药物];

学科分类号：

100403 [营养与食品卫生学]; 100706 [药理学];

摘要：

肿瘤是受到遗传和环境因素影响的系统性疾病,传统的"一病一靶"的药物研发和治疗方式效果不尽人意。网络药理学是近年来新兴的基于"整体论"的新药研发策略,通过网络构建与分析,可为抗肿瘤新药研发提供新的手段和方法。本文简要介绍将网络药理学研究手段用于药物研究的基本概念,并探讨网络药理学在抗肿瘤药物设计、新靶点发现、药物联用设计等方面的应用。随着系统生物学、计算生物学等相关学科的快速发展,网路药理学将在揭示新的肿瘤治疗靶标、治疗药物组合规律以及耐药性的潜在机制等方面为我们提供重要帮助。

引用

页码：1 / 6

页数：6

共 12 条

[1]

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis..Schoeberl Birgit;Pace Emily A;Fitzgerald Jonathan B;Harms Brian D;Xu Lihui;Nie Lin;Linggi Bryan;Kalra Ashish;Paragas Violette;Bukhalid Raghida;Grantcharova Viara;Kohli Neeraj;West Kip A;Leszczyniecka Magdalena;Feldhaus Michael J;Kudla Arthur J;Nielsen Ulrik B;.Science signaling.2009, 77

[2]

Drug repositioning from bench to bedside: Tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer [J].

Nygren, Peter ;

Larsson, Rolf .

ACTA ONCOLOGICA, 2014, 53 (03) :427-428

[3]

Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways [J].

Tang, Jing ;

Karhinen, Leena ;

Xu, Tao ;

Szwajda, Agnieszka ;

Yadav, Bhagwan ;

Wennerberg, Krister ;

Aittokallio, Tero .

PLOS COMPUTATIONAL BIOLOGY, 2013, 9 (09)

[4]

Adopting Network Pharmacology for Cancer Drug Discovery.[J].Asfar S. Azmi.Current Drug Discovery Technologies.2013, 2

[5]

Structure and dynamics of molecular networks: A novel paradigm of drug discovery.[J].Peter Csermely;Tamás Korcsmáros;Huba J.M. Kiss;Gábor London;Ruth Nussinov.Pharmacology and Therapeutics.2013, 3

[6]

Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from na?ve Asian NSCLC patients.[J].Mengmeng Yang;Baoen Shan;Qiaoxia Li;Xiaoming Song;Jie Cai;Jianyun Deng;Likun Zhang;Zhenjian Du;Junjie Lu;Taiping Chen;Jean‐Pierre Wery;Yiyou Chen;Qixiang Li.Int. J. Cancer.2012, 2

[7]

The human phosphotyrosine signaling network: Evolution and hotspots of hijacking in cancer [J].

Li, Lei ;

Tibiche, Chabane ;

Fu, Cong ;

Kaneko, Tomonori ;

Moran, Michael F. ;

Schiller, Martin R. ;

Li, Shawn Shun-Cheng ;

Wang, Edwin .

GENOME RESEARCH, 2012, 22 (07) :1222-1230

[8]

Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks [J].

Lee, Michael J. ;

Ye, Albert S. ;

Gardino, Alexandra K. ;

Heijink, Anne Margriet ;

Sorger, Peter K. ;

MacBeath, Gavin ;

Yaffe, Michael B. .

CELL, 2012, 149 (04) :780-794

[9]

A Systems Pharmacology Analysis of Major Chemotherapy Combination Regimens Used in Gastric Cancer Treatment: Predicting Potential New Protein Targets and Drugs [J].

Rosado, J. O. ;

Henriques, J. A. P. ;

Bonatto, D. .

CURRENT CANCER DRUG TARGETS, 2011, 11 (07) :849-869

[10]

Do cancer proteins really interact strongly in the human protein–protein interaction network?.[J].Junfeng Xia;Jingchun Sun;Peilin Jia;Zhongming Zhao.Computational Biology and Chemistry.2011, 3

← 1 2 →